Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
NCT00406276
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
28
Enrollment
OTHER
Sponsor class
Stopped
data analysis showed insufficient drug efficacy
Conditions
Lung Cancer
Interventions
DRUG:
RAD001
DRUG:
Docetaxel
Sponsor
Emory University